Defining Good Clinical Practice

The International Council for Harmonisation defines Good Clinical Practice in precise terms. Understanding this definition is essential because every requirement in the ICH E6(R3) guideline flows from it.

Understanding GCP's three dimensions

Notice that the Introduction describes GCP as an international, ethical, scientific and quality standard. These are not separate requirements but interconnected dimensions of a single standard. The following is a teaching framework to help illustrate how these dimensions work together — "three pillars" is not official ICH terminology.

The ethical dimension ensures that research respects the dignity, rights, and welfare of every participant. It requires informed consent, oversight by independent ethics committees, and ongoing attention to the balance between potential benefits and risks. A trial that generates useful data but harms participants is not a success; it is a failure of the ethical standard.

The scientific dimension ensures that trials are designed and conducted to produce valid answers to the research questions. This means adequate sample sizes, appropriate comparator groups, predefined endpoints, and statistical methods suited to the study objectives. A trial that protects participants perfectly but cannot answer the scientific question wastes everyone's time and resources.

The quality dimension ensures that the systems and processes supporting the trial are fit for purpose. Data must be accurate, complete, and verifiable. Procedures must be followed consistently. Deviations must be documented and addressed. Quality is not about perfection; it is about ensuring that the trial's conclusions can be trusted.

These three pillars are interdependent. Consider a scenario where a coordinator discovers that a laboratory sample was mislabeled. The quality dimension requires documenting and correcting the error. The scientific dimension requires determining whether the mislabeled data can still be used or must be excluded. The ethical dimension requires considering whether the participant should be notified and whether additional samples are needed. GCP does not treat these as separate considerations; they are facets of a single standard.

The key stakeholders in clinical trials

Clinical trials involve multiple parties with distinct roles and responsibilities. Understanding who does what is fundamental to understanding how GCP works in practice.

The sponsor's role

ICH E6(R3) defines the sponsor as "an individual, company, institution or organisation that takes responsibility for the initiation, management and arrangement of the financing of a clinical trial." Note that the sponsor takes responsibility for these activities — the sponsor does not necessarily perform them all directly. A pharmaceutical company developing a new medication is typically the sponsor. An academic institution conducting investigator-initiated research may also serve as sponsor.

Per Principle 10.1, the sponsor may transfer activities, but retains overall responsibility for those activities. This distinction between transferring activities and retaining overall responsibility is fundamental to the E6(R3) framework. The sponsor must ensure that proper systems exist for trial oversight, that investigators are qualified, that the protocol is scientifically sound, and that data are collected and managed appropriately.

The investigator's role

The investigator is the physician or qualified individual who takes responsibility for conducting the trial at a specific site. The investigator's responsibilities are substantial: reviewing the protocol, ensuring participant safety, making medical decisions about participant care, supervising the research team, and maintaining accurate records.

The investigator must be qualified by education, training, and experience to conduct the trial. This is not a ceremonial role. The investigator personally signs the protocol agreement, accepts responsibility for the conduct of the trial at their site, and is accountable to regulatory authorities for what happens there.

The sub-investigator's role

Sub-investigators are members of the research team designated by the investigator to perform trial-related procedures and make trial-related decisions. A sub-investigator might be a physician who conducts physical examinations, a nurse who administers investigational product, or a coordinator who collects clinical data.

The critical distinction is that sub-investigators work under the investigator's supervision and authority. Their qualifications and delegated tasks must be documented, in a record of delegation. The investigator remains responsible for their work.

The CRO's role

Contract Research Organizations are companies that perform sponsor duties on behalf of the sponsor. A sponsor might contract with a CRO to manage site monitoring, data management, statistical analysis, or regulatory submissions.

Transfer of activities to a CRO does not transfer accountability. The sponsor must ensure the CRO is qualified, must define the transferred activities in a written agreement, and must maintain oversight of the CRO's performance. If a CRO fails to perform adequately, the sponsor is still accountable for that failure.

Service providers: a distinct category

ICH E6(R3) draws a clear line between contract research organizations and service providers. A CRO assumes transferred sponsor responsibilities under Section 3.6—it assumes responsibility for performing specific transferred sponsor activities, though the sponsor retains ultimate responsibility (Section 3.6.6). A service provider, by contrast, performs specific contracted activities without assuming sponsor responsibilities.

The ICH E6(R3) Glossary defines a service provider as "a person or organisation (commercial, academic or other) providing a service used by either the sponsor or the investigator to fulfil trial-related activities." A central laboratory analyzing blood samples, an imaging vendor providing radiological reads, a courier service transporting specimens—these are service providers. They perform essential work, but they do not assume the sponsor's regulatory obligations in the way a CRO does.

This distinction matters for oversight. Section 3.6 requires that when service providers are used, appropriate agreements (3.6.1, 3.6.4) and oversight mechanisms (3.6.9) must be in place. However, the nature of that oversight differs from CRO oversight because the accountability structure differs. The sponsor or investigator engaging a service provider retains full responsibility for the activity; the service provider simply executes a defined scope of work under contract.

Oversight activities: monitoring, audit, and inspection

GCP requires multiple layers of oversight to ensure that trials are conducted properly and that data are reliable. Three distinct activities serve this purpose, each with a different scope and authority.

Monitoring: the sponsor's eyes at the site

Monitoring is the act of overseeing the progress of a clinical trial and of ensuring that it is conducted, recorded and reported in accordance with the protocol, SOPs, GCP and the applicable regulatory requirements. The sponsor is responsible for monitoring, though this activity is often performed by a CRO.

A Clinical Research Associate, commonly called a CRA or monitor, visits trial sites to verify that data recorded in case report forms match source records, that investigational product is being managed correctly, that essential records are in place, and that the site is following the protocol. Monitoring is routine, ongoing, and integrated into normal trial operations.

The monitor does not make medical decisions or direct site staff. Rather, the monitor observes, verifies, and reports findings to the sponsor. When issues are identified, the monitor works with the site to resolve them and documents both the finding and the resolution.

Audit: independent quality evaluation

An audit is a systematic and independent examination of trial-related activities and records. Unlike monitoring, which is performed by the same operational team running the trial, audits are conducted by a separate quality assurance function that reports independently to senior management.

Audits may focus on a specific site, a particular process (such as informed consent or adverse event reporting), or the overall trial conduct. The auditor examines whether established procedures were followed and whether the trial was conducted in compliance with the protocol, GCP, and regulations.

Because audits are independent of trial operations, they can identify systemic issues that monitoring might miss. The sponsor uses audit findings to improve processes and correct deficiencies before they become regulatory problems.

Inspection: regulatory authority oversight

An inspection is an official examination by a regulatory authority to verify compliance with applicable laws and regulations. Regulatory agencies such as the FDA, EMA, or national competent authorities have legal authority to inspect any aspect of a clinical trial.

Inspections may be triggered by a regulatory submission (pre-approval inspection), by concerns raised during application review (for-cause inspection), or as part of routine surveillance. Inspectors have broad authority to examine records, interview staff, and observe trial conduct.

The consequences of inspection findings can be significant. Observations documented on an FDA Form 483 or in an EMA inspection report may require formal response and corrective action. Serious findings can affect approval of the investigational product, result in warning letters, or lead to other enforcement actions.

GCP and national regulatory requirements

ICH GCP is a guideline developed through international harmonization, but clinical trials must also comply with applicable laws and regulations in each country where they are conducted. Understanding this relationship is essential for anyone working in clinical research.

The ICH member regions, which include the United States, European Union, Japan, and other countries, have adopted ICH GCP as part of their regulatory frameworks. When conducting trials in these regions, compliance with ICH GCP is typically a regulatory requirement, not merely a recommendation.

However, national and regional requirements may add to or modify ICH GCP in specific ways. For example, requirements for informed consent documentation, adverse event reporting timelines, or data privacy may vary by jurisdiction. A multi-site international trial must comply with both ICH GCP and the specific requirements of each country where it operates.

Why GCP matters for your work

GCP is not an abstract regulatory concept. It shapes every aspect of how clinical trials are conducted, from the initial protocol design through data analysis and regulatory submission. For investigators and site staff, GCP provides the framework within which all trial activities take place.

When you screen a potential participant, GCP guides how eligibility is assessed and documented. When you obtain informed consent, GCP specifies what information must be provided and how the process must be recorded. When you collect clinical data, GCP requires accuracy, completeness, and verifiability. When problems arise, GCP defines how deviations must be handled and reported.

Understanding GCP is not optional for research professionals. It is the foundation of competent practice.

Defining Good Clinical Practice

The International Council for Harmonisation defines Good Clinical Practice in precise terms. Understanding this definition is essential because every requirement in the ICH E6(R3) guideline flows from it.

Understanding GCP's three dimensions

Notice that the Introduction describes GCP as an international, ethical, scientific and quality standard. These are not separate requirements but interconnected dimensions of a single standard. The following is a teaching framework to help illustrate how these dimensions work together — "three pillars" is not official ICH terminology.

The ethical dimension ensures that research respects the dignity, rights, and welfare of every participant. It requires informed consent, oversight by independent ethics committees, and ongoing attention to the balance between potential benefits and risks. A trial that generates useful data but harms participants is not a success; it is a failure of the ethical standard.

The scientific dimension ensures that trials are designed and conducted to produce valid answers to the research questions. This means adequate sample sizes, appropriate comparator groups, predefined endpoints, and statistical methods suited to the study objectives. A trial that protects participants perfectly but cannot answer the scientific question wastes everyone's time and resources.

The quality dimension ensures that the systems and processes supporting the trial are fit for purpose. Data must be accurate, complete, and verifiable. Procedures must be followed consistently. Deviations must be documented and addressed. Quality is not about perfection; it is about ensuring that the trial's conclusions can be trusted.

These three pillars are interdependent. Consider a scenario where a coordinator discovers that a laboratory sample was mislabeled. The quality dimension requires documenting and correcting the error. The scientific dimension requires determining whether the mislabeled data can still be used or must be excluded. The ethical dimension requires considering whether the participant should be notified and whether additional samples are needed. GCP does not treat these as separate considerations; they are facets of a single standard.

The key stakeholders in clinical trials

Clinical trials involve multiple parties with distinct roles and responsibilities. Understanding who does what is fundamental to understanding how GCP works in practice.

The sponsor's role

ICH E6(R3) defines the sponsor as "an individual, company, institution or organisation that takes responsibility for the initiation, management and arrangement of the financing of a clinical trial." Note that the sponsor takes responsibility for these activities — the sponsor does not necessarily perform them all directly. A pharmaceutical company developing a new medication is typically the sponsor. An academic institution conducting investigator-initiated research may also serve as sponsor.

Per Principle 10.1, the sponsor may transfer activities, but retains overall responsibility for those activities. This distinction between transferring activities and retaining overall responsibility is fundamental to the E6(R3) framework. The sponsor must ensure that proper systems exist for trial oversight, that investigators are qualified, that the protocol is scientifically sound, and that data are collected and managed appropriately.

The investigator's role

The investigator is the physician or qualified individual who takes responsibility for conducting the trial at a specific site. The investigator's responsibilities are substantial: reviewing the protocol, ensuring participant safety, making medical decisions about participant care, supervising the research team, and maintaining accurate records.

The investigator must be qualified by education, training, and experience to conduct the trial. This is not a ceremonial role. The investigator personally signs the protocol agreement, accepts responsibility for the conduct of the trial at their site, and is accountable to regulatory authorities for what happens there.

The sub-investigator's role

Sub-investigators are members of the research team designated by the investigator to perform trial-related procedures and make trial-related decisions. A sub-investigator might be a physician who conducts physical examinations, a nurse who administers investigational product, or a coordinator who collects clinical data.

The critical distinction is that sub-investigators work under the investigator's supervision and authority. Their qualifications and delegated tasks must be documented, in a record of delegation. The investigator remains responsible for their work.

The CRO's role

Contract Research Organizations are companies that perform sponsor duties on behalf of the sponsor. A sponsor might contract with a CRO to manage site monitoring, data management, statistical analysis, or regulatory submissions.

Transfer of activities to a CRO does not transfer accountability. The sponsor must ensure the CRO is qualified, must define the transferred activities in a written agreement, and must maintain oversight of the CRO's performance. If a CRO fails to perform adequately, the sponsor is still accountable for that failure.

Service providers: a distinct category

ICH E6(R3) draws a clear line between contract research organizations and service providers. A CRO assumes transferred sponsor responsibilities under Section 3.6—it assumes responsibility for performing specific transferred sponsor activities, though the sponsor retains ultimate responsibility (Section 3.6.6). A service provider, by contrast, performs specific contracted activities without assuming sponsor responsibilities.

The ICH E6(R3) Glossary defines a service provider as "a person or organisation (commercial, academic or other) providing a service used by either the sponsor or the investigator to fulfil trial-related activities." A central laboratory analyzing blood samples, an imaging vendor providing radiological reads, a courier service transporting specimens—these are service providers. They perform essential work, but they do not assume the sponsor's regulatory obligations in the way a CRO does.

This distinction matters for oversight. Section 3.6 requires that when service providers are used, appropriate agreements (3.6.1, 3.6.4) and oversight mechanisms (3.6.9) must be in place. However, the nature of that oversight differs from CRO oversight because the accountability structure differs. The sponsor or investigator engaging a service provider retains full responsibility for the activity; the service provider simply executes a defined scope of work under contract.

Oversight activities: monitoring, audit, and inspection

GCP requires multiple layers of oversight to ensure that trials are conducted properly and that data are reliable. Three distinct activities serve this purpose, each with a different scope and authority.

Monitoring: the sponsor's eyes at the site

Monitoring is the act of overseeing the progress of a clinical trial and of ensuring that it is conducted, recorded and reported in accordance with the protocol, SOPs, GCP and the applicable regulatory requirements. The sponsor is responsible for monitoring, though this activity is often performed by a CRO.

A Clinical Research Associate, commonly called a CRA or monitor, visits trial sites to verify that data recorded in case report forms match source records, that investigational product is being managed correctly, that essential records are in place, and that the site is following the protocol. Monitoring is routine, ongoing, and integrated into normal trial operations.

The monitor does not make medical decisions or direct site staff. Rather, the monitor observes, verifies, and reports findings to the sponsor. When issues are identified, the monitor works with the site to resolve them and documents both the finding and the resolution.

Audit: independent quality evaluation

An audit is a systematic and independent examination of trial-related activities and records. Unlike monitoring, which is performed by the same operational team running the trial, audits are conducted by a separate quality assurance function that reports independently to senior management.

Audits may focus on a specific site, a particular process (such as informed consent or adverse event reporting), or the overall trial conduct. The auditor examines whether established procedures were followed and whether the trial was conducted in compliance with the protocol, GCP, and regulations.

Because audits are independent of trial operations, they can identify systemic issues that monitoring might miss. The sponsor uses audit findings to improve processes and correct deficiencies before they become regulatory problems.

Inspection: regulatory authority oversight

An inspection is an official examination by a regulatory authority to verify compliance with applicable laws and regulations. Regulatory agencies such as the FDA, EMA, or national competent authorities have legal authority to inspect any aspect of a clinical trial.

Inspections may be triggered by a regulatory submission (pre-approval inspection), by concerns raised during application review (for-cause inspection), or as part of routine surveillance. Inspectors have broad authority to examine records, interview staff, and observe trial conduct.

The consequences of inspection findings can be significant. Observations documented on an FDA Form 483 or in an EMA inspection report may require formal response and corrective action. Serious findings can affect approval of the investigational product, result in warning letters, or lead to other enforcement actions.

GCP and national regulatory requirements

ICH GCP is a guideline developed through international harmonization, but clinical trials must also comply with applicable laws and regulations in each country where they are conducted. Understanding this relationship is essential for anyone working in clinical research.

The ICH member regions, which include the United States, European Union, Japan, and other countries, have adopted ICH GCP as part of their regulatory frameworks. When conducting trials in these regions, compliance with ICH GCP is typically a regulatory requirement, not merely a recommendation.

However, national and regional requirements may add to or modify ICH GCP in specific ways. For example, requirements for informed consent documentation, adverse event reporting timelines, or data privacy may vary by jurisdiction. A multi-site international trial must comply with both ICH GCP and the specific requirements of each country where it operates.

Why GCP matters for your work

GCP is not an abstract regulatory concept. It shapes every aspect of how clinical trials are conducted, from the initial protocol design through data analysis and regulatory submission. For investigators and site staff, GCP provides the framework within which all trial activities take place.

When you screen a potential participant, GCP guides how eligibility is assessed and documented. When you obtain informed consent, GCP specifies what information must be provided and how the process must be recorded. When you collect clinical data, GCP requires accuracy, completeness, and verifiability. When problems arise, GCP defines how deviations must be handled and reported.

Understanding GCP is not optional for research professionals. It is the foundation of competent practice.